Abstract

Nonalcoholic steatohepatitis (NASH) is a major health problem since it often leads to hepatocellular carcinoma. However, the underlying mechanisms of NASH development and subsequent fibrosis have yet to be clarified. We compared comprehensive lipidomic profiles between mice with high fat diet (HFD)-induced steatosis and STAM mice with NASH and subsequent fibrosis. The STAM mouse is a model that demonstrates NASH progression resembling the disease in humans: STAM mice manifest NASH at 8 weeks, which progresses to fibrosis at 12 weeks, and finally develop hepatocellular carcinoma. Overall, 250 lipid molecules were detected in the liver using liquid chromatography-mass spectrometry. We found that STAM mice with NASH presented a significantly higher abundance of sphingolipids and lower levels of triacylglycerols than the HFD-fed control mice. The abundance of certain fatty acids in phospholipid side chains was also significantly different between STAM and control mice, although global levels of phosphatidylcholines and phosphatidylethanolamines were comparable. Finally, increase in levels of acylcarnitines and some diacylglycerols was observed in STAM mice toward the fibrosis stage, but not in age-matched control mice. Our study provides insights into the lipid status of the steatotic, NASH, and fibrotic liver that would help elucidate the molecular pathophysiology of NASH progression.

Highlights

  • Nonalcoholic steatohepatitis (NASH) is a major health problem since it often leads to hepatocellular carcinoma

  • About 10% of Nonalcoholic fatty liver disease (NAFLD) patients are reported to develop nonalcoholic steatohepatitis (NASH), in which hepatic steatosis is accompanied by inflammation and hepatocyte apoptosis[4,5,6]

  • Another report has demonstrated that stearoyl-CoA desaturase (SCD1), an enzyme that synthesizes monounsaturated fatty acids from saturated fatty acids, plays an important role in hepatic lipid accumulation and NASH progression[10]

Read more

Summary

Introduction

Nonalcoholic steatohepatitis (NASH) is a major health problem since it often leads to hepatocellular carcinoma. The STAM mouse is a model that demonstrates NASH progression resembling the disease in humans: STAM mice manifest NASH at 8 weeks, which progresses to fibrosis at 12 weeks, and develop hepatocellular carcinoma. Depletion of the palmitate elongase, Elovl[6], attenuated NASH progression in mice, and expression of Elovl[6] was positively correlated with severity of steatosis and liver injury in human NASH patients[11]. These observations focused only on free fatty acids, and detailed differences in overall lipid profiles at different stages of the disease have not been characterized. We hypothesized that characterization of lipid status using lipidomics would help illuminate the mechanism of NASH progression

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call